logo-loader
viewNuvectra Corp

Nuvectra wounded after 1Q earnings miss, FDA application delay

The neurostimulation medical-device company posted a wider loss than analysts had expected

neurons
Revenue from Algovita, the company’s flagship spinal cord stimulation system, increased 22% year-over-year to $11 million

Nuvectra Corp (NASDAQ:NVTR), a neurostimulation medical-device company, reported a first-quarter loss late Wednesday that was wider than Street expectations.

The company posted a net loss of $0.83 per share on revenue of $11.1 million, while analysts expected a $0.66 loss on $12 million in revenue.

Shares collapsed 30% to $6.55 Thursday afternoon.

Revenue from Algovita, the company’s flagship spinal cord stimulation system, increased 22% year over year to $11 million.

“Our primary focus remains on advancing Algovita to deliver stronger results through the duration of 2019,” CEO Fred Parks said. “We are continuing to drive our clinical efforts, accelerating productivity, and increasing our sales force from approximately 60 territories as of May 1, 2019 to approximately 75 by year end. Therefore, we are introducing full year 2019 Algovita revenue guidance of $57-62 million.”

The Plano, Texas company also announced it was providing additional information to the FDA regarding its premarket approval application for Virtis, its sacral nerve stimulation treatment for chronic urinary retention.

It expects to submit the information near the end of 2019, pushing back potential approval to early 2020.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Nuvectra Corp

Price: - -

NASDAQ:NVTR
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Covid Technologies looking for large growth after being...

Micron Waste Technologies (CSE: MWM- OTC: MICWF) soon to be subsidiary COVID Technologies President Harvey Sidhu joined Steve Darling from Proactive Vancouver to discuss his company being acquired by Micron. Sidhu discusses his company which makes PPE or personal protective equipment....

45 minutes ago

2 min read